Novartis (NVS) Set to Post Quarterly Earnings on Tuesday

Novartis (NYSE:NVS) is anticipated to post its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of $2.25 per share and revenue of $14.56 billion for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:00 AM ET.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The company had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. On average, analysts expect Novartis to post $8.91 EPS for the current fiscal year and $9.81 EPS for the next fiscal year.

Novartis Price Performance

Shares of NYSE NVS opened at $150.16 on Tuesday. The firm has a market cap of $286.54 billion, a P/E ratio of 22.65, a price-to-earnings-growth ratio of 2.73 and a beta of 0.41. The business’s 50 day moving average is $148.21 and its 200-day moving average is $150.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. Novartis has a 1-year low of $121.57 and a 1-year high of $170.46.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Royal Bank Of Canada started coverage on Novartis in a research note on Tuesday, September 8th. They issued a “sector perform” rating for the company. Berenberg Bank lowered their price objective on Novartis from $147.00 to $130.00 and set a “hold” rating on the stock in a research report on Friday, September 11th. Bank of America reissued a “buy” rating on shares of Novartis in a report on Tuesday, September 8th. HSBC raised shares of Novartis from a “reduce” rating to a “hold” rating and boosted their target price for the company from $123.00 to $136.00 in a research report on Thursday, September 10th. Finally, Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of Novartis in a research note on Thursday, September 17th. Six equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Novartis presently has an average rating of “Hold” and a consensus target price of $145.60.

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.